John Port1, Balwinder Singh2, and Mark A Frye2
1Mayo Clinic, Rochester, MN, United States, 2Department of Psychiatry, Mayo Clinic, Rochester, MN, United States
Synopsis
We have developed a method of optimally frequency/phase
adjusting individual FIDS of an MRS acquisition such that patient motion and
scanner artifacts can be eliminated from long MRS acquisitions. This method uses MRS peak symmetry in order
to optimally phase the Cho and Cr peaks acquired using a frequency-locked
MEGA-PRESS sequence. We tested our method subjects receiving an IV ketamine
infusion for MDD and noticed dramatic changes in GABA and Glx levels in one
subject. Our method allows for dynamic MRS studies that can measure
neurotransmitter changes over time.
Introduction
Major depressive disorder (MDD) affects one in four people1. Ketamine infusions have recently been shown
to relieve symptoms in treatment-resistant MDD patients. The effect(s) of ketamine on brain glutamate
and GABA levels has only recently been studied2.
Several challenges have limited these studies. For the MEGA-PRESS sequence, scanner B0
drift over time and patient motion artifacts cause the saturation pulse to move
off the C3 GABA resonance at 1.89 ppm, leading to incomplete saturation/spurious
GABA measurements. As such, dynamic studies of glutamate and GABA to date have
been limited to a series of short separate MRS acquisitions.
The purposes of this study were to 1) develop a robust,
artifact-resistant MEGA-PRESS analysis pipeline that overcomes these
limitations, and 2) use the pipeline to detect glutamate and GABA changes during
a ketamine infusion.Method
This study was conducted with approval from our
institutional review board (IRB #17-011373). All subjects provided written
informed consent. A Siemens 3T Prisma MEGA-PRESS (Siemens WIP 859G running on VE11C)
sequence was used to acquire data from a 3.0cm SI x 3.0cm RL x 2.5cm AP MRS
voxel placed in the midline, centered on the pregenual anterior cingulate
cortex (TR=2000ms, TE=68ms, BW=5000Hz, pts=2048, OnSat=1.9ppm, OffSat=7.5ppm,
CHESS water suppression, 32-channel head coil).
This sequence dynamically adjusts the center frequency of water to keep
the saturation pulse properly centered.
A total of 795 MEGA-PRESS ON-OFF pairs were acquired continuously over a
53 minute time period. At 13 minutes into
the acquisition, a 40-minute long IV infusion of ketamine was started. A short
water-reference scan (16 ON-OFF pairs) was acquired before the main sequence.
Water-saturated and water-reference data were split into ON
FIDs and OFF FIDs. Each individual FID
was then frequency and phase adjusted by iterating through frequency (-10 to 10
Hz in 1 Hz increments) and phase (-pi to pi in pi/90 increments) space. The adjusted FID was Fourier-transformed, and
separate Symmetry Indexes (SI) (Figure 1) were computed for the choline (Cho)
and creatine (Cr) peaks. The Cho and Cr
SI for each point in frequency/phase space were combined by first normalizing
the SI in each frequency/phase space to the maximum SI for that space, then
adding them up. Finally, the combined SI
data were evaluated to determine the best frequency and phase values for that
FID, and the FID adjusted with those values.
Following frequency and phase correction, sliding window
analysis was performed on the data. A
time window 13 minutes (195 ON-OFF pairs) long per Brix3 was slid across
the data set in increments of one minute (15 ON-OFF pairs). The corrected ON and OFF FIDS in the window were
separately averaged together. The
DIFFERENCE FID was then computed as the ON FID minus the OFF FID. The 41 OFF
and DIFFERENCE FIDS were then processed using LCModel4 to create a
total of 41 consecutive datasets from which GABA and Glu could be plotted as a
function of time. All metabolite data
were water-scaled.Results
Figure 2 demonstrates the best frequency and phase
corrections used for each of the 1590 FIDS in order to obtain the highest peak
SI value. Note the rather large swings
in frequency and smaller adjustments in phase, compared to the relatively
stable peak SI values.
Figure 3 shows a typical difference spectrum obtained from
the midline anterior cingulate cortex computed from a 13-minute wide sliding
window in Subject D. The shim on this
scan was marginal due to the large size of the voxel and the adjacency to the
patient’s frontal and ethmoid sinuses.
Table 1 shows the data evaluating the selection of the best
a priori knowledge parameters. The
center of the Cho peak was set at 3.200 ppm and the Cr peak center selected to
be “delta ppm” to the right. The mean
FWHM, SNR and various LCModel CRLB values were computed for each of the 795
ON-OFF pairs for the various Cr peak positions.
Per Govindaraju5 the theoretical difference between the
centers of the Cho and Cr peaks is 0.158 ppm (green box). Interestingly, the lowest CRLB for GABA, Glx
and NAA+NAAG in the DIFFERENCE spectrum were obtained using this theoretical shift,
whereas the best SI was obtained using a Cho-Cr separation of 0.178 ppm.
Figure 4 shows the GABA, Glx and NAA+NAAG values obtained from
the DIFF spectrum from four subjects during their ketamine infusions. Note that Subjects A, C and D show relatively
little change following ketamine infusion, while Subject B has dramatic changes
in GABA and Glx following ketamine infusion.Discussion
The combination of sequence frequency-locking to water and using
peak symmetry to frequency and phase adjust individual FIDS in long MEGA-PRESS
acquisitions appears to have overcome the challenging issues that previously
limited dynamic applications of MEGA-PRESS.
The SI technique is able to correct for patient motion and scanner drift
artifacts despite relatively noisy individual FIDS. Conclusion
This new method of acquiring and post-processing dynamic
GABA and Glx data can now be used to study patients over long periods of time,
opening up the possibility of drug response trials that can measure acute changes
in neurotransmitters as a drug is infused into the patient.Acknowledgements
No acknowledgement found.References
1.
World Health Organization. Global Burden
of Disease. Geneva, Switzerland: World Health Organization; 2002.
2.
Milak
MS, Proper CJ, Mulhern ST et al. A pilot in
vivo proton magnetic resonance spectroscopy study of amino acid
neurotransmitter response to ketamine treatment of major depressive disorder. Mol.
Psychiatry 2016; 21:320-327
3.
Brix
MK, Ersland L, Hugdahl K et al. Within- and between-session reproducibility of
GABA measurements with MR spectroscopy. JMRI 2016; 46:421-430
4.
Provencher
SW. Estimation of metabolite concentrations from localized in vivo proton NMR
spectra. MRM 1993; 30:672-679
5.
Govindaraju
V, Young K and Maudsley AA. Proton NMR
chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000;
13:129-153